The market is panicking over a French IT vault. Here is the ruthless math on why it’s a structural mispricing.

Algorithms and weak hands are currently selling down the French IT consultancy Neurones (NRO) ahead of tomorrow's earnings report. The market is pricing in the fear of a broader IT sector slowdown, doing what a blind market always does: de-risking without actually looking at the balance sheet.
But if you strip away the narrative and look purely at the financial physics, Neurones is currently one of the most absurd mathematical anomalies on the market.
Here is the ruthless autopsy of why this price drop is an optical illusion.
1. The Cash Anchor (Absolute Armor)
Everything starts with the balance sheet. Neurones currently trades at a market cap of roughly €837 million.
Look under the hood: the company is sitting on a massive, clean net cash position of over €282 million. That means more than a third of the entire market cap is covered by hard cash sitting in the bank.
Deduct this cash anchor, and the actual Enterprise Value (EV) shrinks to just €555 million.
2. The Engine (Hard Cash Yield)
Neurones is not a capex-heavy industrial. It is an asset-light compounder. Under a strict framework, an asset-light machine like this only requires a 4.0% Free Cash Flow (FCF) yield to be fairly valued.
Historically, this company churns out over €74 million in clean, bottom-line FCF annually.
Divide that €74 million of hard cash generation by the €555 million EV, and you get an absolutely absurd FCF yield of over 13%.
3. The Kinetic Trap (Asymmetric Upside)
What happens if the market stays blind and the stock price doesn't go up? Nothing. That is actually the optimal scenario for a shareholder.
A company generating a 13% yield on its EV with a €282 million war chest can simply cannibalize its own float. If management deploys that cash to aggressively buy back and destroy shares at these depressed prices, your ownership of the underlying earnings grows exponentially without you putting in another dime. The denominator shrinks, and the math takes over.
The Verdict
Tomorrow's earnings are just short-term noise. Buying Neurones at this price means you aren't paying for hope or analyst growth projections. You are buying a heavily armored balance sheet and a 13% hard cash yield. The market can panic about the IT cycle all it wants, but it cannot outrun the math.